Human leukocyte antigen polymorphisms and personalized medicine for rheumatoid arthritis

Journal of Human Genetics

Volumn 60, Issue 11, 2015, Pages 691-696

  Furukawa, Hiroshi ^a,c   Oka, Shomi ^a   Shimada, Kota ^a,b   Hashimoto, Atsushi ^a   Tohma, Shigeto ^a  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b TOKYO METROPOLITAN TAMA MEDICAL CENTER   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALLOPURINOL; AMOXICILLIN; AUTOANTIBODY; BUCILLAMINE; CALRETICULIN; CARBAMAZEPINE; CLAVULANIC ACID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD SALT; HLA ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LA ANTIBODY; LEFLUNOMIDE; METHOTREXATE; NITRIC OXIDE; PENICILLAMINE; REACTIVE OXYGEN METABOLITE; RHEUMATOID FACTOR; RO ANTIBODY; TACROLIMUS; THIAMAZOLE; TICLOPIDINE; TIOPRONIN; ANTIRHEUMATIC AGENT;

AGRANULOCYTOSIS; ALLELE; AMINO ACID SEQUENCE; CHOLESTASIS; DRUG HYPERSENSITIVITY; ETHNIC DIFFERENCE; ETHNIC GROUP; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY; HETEROZYGOTE; HLA SYSTEM; HUMAN; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOPROLIFERATIVE DISEASE; MEMBRANOUS GLOMERULONEPHRITIS; MYOPATHY; PERSONALIZED MEDICINE; PHENOTYPE; PROTEINURIA; REVIEW; RHEUMATOID ARTHRITIS; STEVENS JOHNSON SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; ARTHRITIS, RHEUMATOID; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG HYPERSENSITIVITY; GENETIC PREDISPOSITION TO DISEASE; HLA ANTIGENS; HUMANS; POLYMORPHISM, GENETIC; PRECISION MEDICINE;

EID: 84947771875     PISSN: 14345161     EISSN: 1435232X     Source Type: Journal    
DOI: 10.1038/jhg.2015.36     Document Type: Review

References (97)

1. The MHC sequencing consortium. Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature 401, 921-923 (1999).
2. Perricone, C., Ceccarelli, F. & Valesini, G. An overview on the genetic of rheumatoid arthritis: a never-ending story. Autoimmun. Rev. 10, 599-608 (2011).
3. MacGregor, A. J., Snieder, H., Rigby, A. S., Koskenvuo, M., Kaprio, J. & Aho, K. et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 43, 30-37 (2000).
4. van der Woude, D., Houwing-Duistermaat, J. J., Toes, R. E., Huizinga, T. W., Thomson, W. & Worthington, J. et al. Quantitative heritability of anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum. 60, 916-923 (2009).
5. Scott, D. L., Wolfe, F. & Huizinga, T. W. Rheumatoid arthritis. Lancet 376, 1094-1108 (2010).
6. Stastny, P. Mixed lymphocyte cultures in rheumatoid arthritis. J. Clin. Invest. 57, 1148-1157 (1976).
7. Okada, Y., Wu, D., Trynka, G., Raj, T., Terao, C. & Ikari, K. et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506, 376-381 (2014).
8. Viatte, S., Plant, D. & Raychaudhuri, S. Genetics and epigenetics of rheumatoid arthritis. Nat. Rev. Rheumatol. 9, 141-153 (2013).
9. Gregersen, P. K., Silver, J. & Winchester, R. J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30, 1205-1213 (1987).
10. Gonzalez, A., Nicovani, S., Massardo, L., Bull, P., Rodriguez, L. & Jacobelli, S. Novel genetic markers of rheumatoid arthritis in Chilean patients, by DR serotyping and restriction fragment length polymorphism analysis. Arthritis Rheum. 35, 282-289 (1992).
11. Wakitani, S., Imoto, K., Murata, N., Toda, Y., Ogawa, R. & Ochi, T. The homozygote of HLA-DRB1∗0901, not its heterozygote, is associated with rheumatoid arthritis in Japanese. Scand. J. Rheumatol. 27, 381-382 (1998).
12. Milicic, A., Lee, D., Brown, M. A., Darke, C. & Wordsworth, B. P. HLA-DR/DQ haplotype in rheumatoid arthritis: novel allelic associations in UK Caucasians. J. Rheumatol. 29, 1821-1826 (2002).
13. Lee, H. S., Lee, K. W., Song, G. G., Kim, H. A., Kim, S. Y. & Bae, S. C. Increased susceptibility to rheumatoid arthritis in Koreans heterozygous for HLA-DRB1∗0405 and ∗0901. Arthritis Rheum. 50, 3468-3475 (2004).
14. du Montcel, S. T., Michou, L., Petit-Teixeira, E., Osorio, J., Lemaire, I. & Lasbleiz, S. et al. New classification of HLA-DRB1 alleles supports the shared epitope hypothesis of rheumatoid arthritis susceptibility. Arthritis Rheum. 52, 1063-1068 (2005).
15. Pratesi, F., Petit Teixeira, E., Sidney, J., Michou, L., Puxeddu, I. & Sette, A. et al. HLA shared epitope and ACPA: just a marker or an active player? Autoimmun. Rev. 12, 1182-1187 (2013).
16. Jardetzky, T. S., Brown, J. H., Gorga, J. C., Stern, L. J., Urban, R. G. & Chi, Y. I. et al. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 368, 711-718 (1994).
17. Singal, D. P., D'Souza, M., Reid, B., Bensen, W. G., Kassam, Y. B. & Adachi, J. D. HLA-DQ beta-chain polymorphism in HLA-DR4 haplotypes associated with rheumatoid arthritis. Lancet 2, 1118-1120 (1987).
18. Hall, F. C., Weeks, D. E., Camilleri, J. P., Williams, L. A., Amos, N. & Darke, C. et al. Influence of the HLA-DRB1 locus on susceptibility and severity in rheumatoid arthritis. Qjm 89, 821-829 (1996).
19. Erlich, H., Valdes, A. M., Noble, J., Carlson, J. A., Varney, M. & Concannon, P. et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 57, 1084-1092 (2008).
20. Shimane, K., Kochi, Y., Suzuki, A., Okada, Y., Ishii, T. & Horita, T. et al. An association analysis of HLA-DRB1 with systemic lupus erythematosus and rheumatoid arthritis in a Japanese population: effects of ∗09:01 allele on disease phenotypes. Rheumatology (Oxford) 52, 1172-1182 (2013).
21. Holoshitz, J. The quest for better understanding of HLA-disease association: scenes from a road less travelled by. Discov. Med. 16, 93-101 (2013).
22. van der Woude, D., Lie, B. A., Lundstrom, E., Balsa, A., Feitsma, A. L. & Houwing-Duistermaat, J. J. et al. Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1∗1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations. Arthritis Rheum. 62, 1236-1245 (2010).
23. Oka, S., Furukawa, H., Kawasaki, A., Shimada, K., Sugii, S. & Hashimoto, A. et al. Protective effect of the HLA-DRB1∗13:02 allele in Japanese rheumatoid arthritis patients. PLoS ONE 9, e99453 (2014).
24. Tsai, S. & Santamaria, P. MHC class II polymorphisms, autoreactive T-cells, and autoimmunity. Front. Immunol. 4, 321 (2013).
25. Feitsma, A. L., Worthington, J., van der Helm-van Mil, A. H., Plant, D., Thomson, W. & Ursum, J. et al. Protective effect of noninherited maternal HLA-DR antigens on rheumatoid arthritis development. Proc. Natl Acad. Sci. USA 104, 19966-19970 (2007).
26. Raychaudhuri, S., Sandor, C., Stahl, E. A., Freudenberg, J., Lee, H. S. & Jia, X. et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat. Genet. 44, 291-296 (2012).
27. Morgan, A. W., Thomson, W., Martin, S. G., Carter, A. M., Erlich, H. A. & Barton, A. et al. Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population. Arthritis Rheum. 60, 2565-2576 (2009).
28. Jin, H., Arase, N., Hirayasu, K., Kohyama, M., Suenaga, T. & Saito, F. et al. Autoantibodies to IgG/HLA class II complexes are associated with rheumatoid arthritis susceptibility. Proc. Natl Acad. Sci. USA 111, 3787-3792 (2014).
29. Kroot, E. J., de Jong, B. A., van Leeuwen, M. A., Swinkels, H., van den Hoogen, F. H. & van't Hof, M. et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 43, 1831-1835 (2000).
30. Makinen, H., Hannonen, P. & Sokka, T. Sex: a major predictor of remission as measured by 28-joint Disease Activity Score (DAS28) in early rheumatoid arthritis? Ann. Rheum. Dis. 67, 1052-1053 (2008).
31. Klaasen, R., Cantaert, T., Wijbrandts, C. A., Teitsma, C., Gerlag, D. M. & Out, T. A. et al. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study. Rheumatology (Oxford) 50, 1487-1493 (2011).
32. Mori, S., Hirose, J. & Yonemura, K. Contribution of HLA-DRB1∗04 alleles and anticyclic citrullinated antibodies to development of resistance to disease-modifying antirheumatic drugs in early rheumatoid arthritis. Clin. Rheumatol. 29, 1357-1366 (2010).
33. Holoshitz, J. The rheumatoid arthritis HLA-DRB1 shared epitope. Curr. Opin. Rheumatol. 22, 293-298 (2010).
34. Terao, C., Ohmura, K., Ikari, K., Kochi, Y., Maruya, E. & Katayama, M. et al. ACPA-negative RA consists of two genetically distinct subsets based on RF positivity in Japanese. PLoS ONE 7, e40067(2012).
35. Verpoort, K. N., van Gaalen, F. A., van der Helm-van Mil, A. H., Schreuder, G. M., Breedveld, F. C. & Huizinga, T. W. et al. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum. 52, 3058-3062 (2005).
36. Padyukov, L., Seielstad, M., Ong, R. T., Ding, B., Ronnelid, J. & Seddighzadeh, M. et al. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann. Rheum. Dis. 70, 259-265 (2011).
37. Bossini-Castillo, L., de Kovel, C., Kallberg, H., van't Slot, R., Italiaander, A. & Coenen, M. et al. A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides. Ann. Rheum. Dis. 74, e15 (2015).
38. Han, B., Diogo, D., Eyre, S., Kallberg, H., Zhernakova, A. & Bowes, J. et al. Fine mapping seronegative and seropositive rheumatoid arthritis to shared and distinct HLA alleles by adjusting for the effects of heterogeneity. Am. J. Hum. Genet. 94, 522-532 (2014).
39. Padyukov, L., Silva, C., Stolt, P., Alfredsson, L. & Klareskog, L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum. 50, 3085-3092 (2004).
40. Kallberg, H., Padyukov, L., Plenge, R. M., Ronnelid, J., Gregersen, P. K. & van der Helm-van Mil, A. H. et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am. J. Hum. Genet. 80, 867-875 (2007).
41. Lundstrom, E., Kallberg, H., Alfredsson, L., Klareskog, L. & Padyukov, L. Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important. Arthritis Rheum. 60, 1597-1603 (2009).
42. Klareskog, L., Malmstrom, V., Lundberg, K., Padyukov, L. & Alfredsson, L. Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis. Semin. Immunol. 23, 92-98 (2011).
43. Furukawa, H., Oka, S., Shimada, K., Sugii, S., Hashimoto, A. & Komiya, A. et al. Association of increased frequencies of HLA-DPB1∗05:01 with the presence of anti-Ro/SS-A and anti-La/SS-B antibodies in Japanese rheumatoid arthritis and systemic lupus erythematosus patients. PLoS ONE 8, e53910 (2013).
44. Turesson, C., Weyand, C. M. & Matteson, E. L. Genetics of rheumatoid arthritis: is there a pattern predicting extraarticular manifestations? Arthritis Rheum. 51, 853-863 (2004).
45. Lanchbury, J. S., Jaeger, E. E., Sansom, D. M., Hall, M. A., Wordsworth, P. & Stedeford, J. et al. Strong primary selection for the Dw4 subtype of DR4 accounts for the HLA-DQw7 association with Felty's syndrome. Hum. Immunol. 32, 56-64 (1991).
46. Weyand, C. M., Xie, C. & Goronzy, J. J. Homozygosity for the HLA-DRB1 allele selects for extraarticular manifestations in rheumatoid arthritis. J. Clin. Invest. 89, 2033-2039 (1992).
47. Kim, H. Y., Min, J. K., Yang, H. I., Park, S. H., Hong, Y. S. & Jee, W. H. et al. The impact of HLA-DRB1∗0405 on disease severity in Korean patients with seropositive rheumatoid arthritis. Br. J. Rheumatol. 36, 440-443 (1997).
48. Migita, K., Nakamura, T., Koga, T. & Eguchi, K. HLA-DRB1 alleles and rheumatoid arthritis-related pulmonary fibrosis. J. Rheumatol. 37, 205-207 (2010).
49. Furukawa, H., Oka, S., Shimada, K., Sugii, S., Ohashi, J. & Matsui, T. et al. Association of human leukocyte antigen with interstitial lung disease in rheumatoid arthritis: a protective role for shared epitope. PLoS ONE 7, e33133 (2012).
50. Mori, S., Koga, Y. & Sugimoto, M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir. Med. 106, 1591-1599 (2012).
51. Turesson, C., Schaid, D. J., Weyand, C. M., Jacobsson, L. T., Goronzy, J. J. & Petersson, I. F. et al. The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis. Arthritis Res. Ther. 7, R1386-R1393 (2005).
52. Radoux, V., Menard, H. A., Begin, R., Decary, F. & Koopman, W. J. Airways disease in rheumatoid arthritis patients. One element of a general exocrine dysfunction. Arthritis Rheum. 30, 249-256 (1987).
53. Hashimoto, A., Chiba, N., Tsuno, H., Komiya, A., Furukawa, H. & Matsui, T. et al. Incidence of malignancy and the risk of lymphoma in japanese patients with rheumatoid arthritis compared to the general population. J. Rheumatol. (2015)140533 (2015).
54. Yamakawa, N., Fujimoto, M., Kawabata, D., Terao, C., Nishikori, M. & Nakashima, R. et al. A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders. J. Rheumatol. 41, 293-299 (2014).
55. Bridges, S. L. Jr., Hughes, L. B., Mikuls, T. R., Howard, G., Tiwari, H. K. & Alarcon, G. S. et al. Early rheumatoid arthritis in African-Americans: the CLEAR Registry. Clin. Exp. Rheumatol. 21 (5 Suppl 31), S138-S145 (2003).
56. Alamanos, Y. & Drosos, A. A. Epidemiology of adult rheumatoid arthritis. Autoimmun. Rev. 4, 130-136 (2005).
57. Teller, K., Budhai, L., Zhang, M., Haramati, N., Keiser, H. D. & Davidson, A. HLA-DRB1 and DQB typing of Hispanic American patients with rheumatoid arthritis: the "shared epitope" hypothesis may not apply. J. Rheumatol. 23, 1363-1368 (1996).
58. McDaniel, D. O., Alarcon, G. S., Pratt, P. W. & Reveille, J. D. Most African-American patients with rheumatoid arthritis do not have the rheumatoid antigenic determinant (epitope). Ann. Intern. Med. 123, 181-187 (1995).
59. Hughes, L. B., Morrison, D., Kelley, J. M., Padilla, M. A., Vaughan, L. K. & Westfall, A. O. et al. The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture. Arthritis Rheum. 58, 349-358 (2008).
60. Lundstrom, E., Kallberg, H., Smolnikova, M., Ding, B., Ronnelid, J. & Alfredsson, L. et al. Opposing effects of HLA-DRB1∗13 alleles on the risk of developing anticitrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum. 60, 924-930 (2009).
61. Okada, Y., Kim, K., Han, B., Pillai, N. E., Ong, R. T. & Saw, W. Y. et al. Risk for ACPA-positive rheumatoid arthritis is driven by shared HLA amino acid polymorphisms in Asian and European populations. Hum. Mol. Genet. 23, 6916-6926 (2014).
62. Reynolds, R. J., Ahmed, A. F., Danila, M. I., Hughes, L. B., Gregersen, P. K. & Raychaudhuri, S. et al. HLA-DRB1-associated rheumatoid arthritis risk at multiple levels in African Americans: hierarchical classification systems, amino acid positions, and residues. Arthritis Rheumatol. 66, 3274-3282 (2014).
63. Hung, S. I., Chung, W. H., Liou, L. B., Chu, C. C., Lin, M. & Huang, H. P. et al. HLA-B∗5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102, 4134-4139 (2005).
64. Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A. M. & Moore, C. et al. Association between presence of HLA-B∗5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727-732 (2002).
65. Hetherington, S., Hughes, A. R., Mosteller, M., Shortino, D., Baker, K. L. & Spreen, W. et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121-1122 (2002).
66. Chung, W. H., Hung, S. I., Hong, H. S., Hsih, M. S., Yang, L. C. & Ho, H. C. et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428, 486 (2004).
67. Ozeki, T., Mushiroda, T., Yowang, A., Takahashi, A., Kubo, M. & Shirakata, Y. et al. Genome-wide association study identifies HLA-A∗3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 20, 1034-1041 (2011).
68. McCormack, M., Alfirevic, A., Bourgeois, S., Farrell, J. J., Kasperaviciute, D. & Carrington, M. et al. HLA-A∗3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364, 1134-1143 (2011).
69. Shirato, S., Kagaya, F., Suzuki, Y. & Joukou, S. Stevens-Johnson syndrome induced by methazolamide treatment. Arch. Ophthalmol. 115, 550-553 (1997).
70. Tamai, H., Sudo, T., Kimura, A., Mukuta, T., Matsubayashi, S. & Kuma, K. et al. Association between the DRB1∗08032 histocompatibility antigen and methimazole-induced agranulocytosis in Japanese patients with Graves disease. Ann. Intern. Med. 124, 490-494 (1996).
71. Hirata, K., Takagi, H., Yamamoto, M., Matsumoto, T., Nishiya, T. & Mori, K. et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J. 8, 29-33 (2008).
72. Kurosaki, M., Takagi, H. & Mori, M. HLA-A33/B44/DR6 is highly related to intrahepatic cholestasis induced by tiopronin. Dig. Dis. Sci. 45, 1103-1108 (2000).
73. Daly, A. K., Donaldson, P. T., Bhatnagar, P., Shen, Y., Pe'er, I. & Floratos, A. et al. HLA-B∗5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41, 816-819 (2009).
74. Hautekeete, M. L., Horsmans, Y., Van Waeyenberge, C., Demanet, C., Henrion, J. & Verbist, L. et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 117, 1181-1186 (1999).
75. Mammen, A. L., Gaudet, D., Brisson, D., Christopher-Stine, L., Lloyd, T. E. & Leffell, M. S. et al. Increased frequency of DRB1∗11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res. (Hoboken) 64, 1233-1237 (2012).
76. Wei, C. Y., Chung, W. H., Huang, H. W., Chen, Y. T. & Hung, S. I. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J. Allergy Clin. Immunol. 129, 1562-1569 (2012).
77. Illing, P. T., Vivian, J. P., Dudek, N. L., Kostenko, L., Chen, Z. & Bharadwaj, M. et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 486, 554-558 (2012).
78. Maddocks, J. L. & Slater, D. N. Toxic epidermal necrolysis, agranulocytosis and erythroid hypoplasia associated with sulphasalazine. J. R. Soc. Med. 73, 587-588 (1980).
79. Balci, D. D., Peker, E., Duran, N. & Dogramaci, C. A. Sulfasalazine-induced hypersensitivity syndrome in a 15-year-old boy associated with human herpesvirus-6 reactivation. Cutan. Ocul. Toxicol. 28, 45-47 (2009).
80. Tremblay, L., Pineton de Chambrun, G., De Vroey, B., Lavogiez, C., Delaporte, E. & Colombel, J. F. et al. Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases. J. Crohns Colitis 5, 457-460 (2011).
81. Jeung, Y. J., Lee, J. Y., Oh, M. J., Choi, D. C. & Lee, B. J. Comparison of the causes and clinical features of drug rash with eosinophilia and systemic symptoms and stevens-johnson syndrome. Allergy Asthma Immunol. Res. 2, 123-126 (2010).
82. Hall, C. L., Jawad, S., Harrison, P. R., MacKenzie, J. C., Bacon, P. A. & Klouda, P. T. et al. Natural course of penicillamine nephropathy: a long term study of 33 patients. Br. Med. J. 296, 1083-1086 (1988).
83. Hall, C. L., Fothergill, N. J., Blackwell, M. M., Harrison, P. R., MacKenzie, J. C. & MacIver, A. G. The natural course of gold nephropathy: long term study of 21 patients. Br Med J 295, 745-748 (1987).
84. Obayashi, M., Uzu, T., Harada, T., Yamato, M., Takahara, K. & Yamauchi, A. Clinical course of bucillamine-induced nephropathy in patients with rheumatoid arthritis. Clin. Exp. Nephrol. 7, 275-278 (2003).
85. Ueda, S., Wakashin, M., Wakashin, Y., Yoshida, H., Iesato, K. & Mori, T. et al. Experimental gold nephropathy in guinea pigs: detection of autoantibodies to renal tubular antigens. Kidney Int. 29, 539-548 (1986).
86. Smith, W. & Ball, G. V. Lung injury due to gold treatment. Arthritis Rheum. 23, 351-354 (1980).
87. Shidara, K., Hoshi, D., Inoue, E., Yamada, T., Nakajima, A. & Taniguchi, A. et al. Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA. Mod. Rheumatol. 20, 280-286 (2010).
88. Sawada, T., Inokuma, S., Sato, T., Otsuka, T., Saeki, Y. & Takeuchi, T. et al. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 48, 1069-1072 (2009).
89. Koike, R., Tanaka, M., Komano, Y., Sakai, F., Sugiyama, H. & Nanki, T. et al. Tacrolimus-induced pulmonary injury in rheumatoid arthritis patients. Pulm. Pharmacol. Ther. 24, 401-406 (2011).
90. Furukawa, H., Oka, S., Shimada, K.Rheumatoid Arthritis-Interstitial Lung Disease Study Consortium, Tsuchiya, N. & Tohma, S. HLA-A∗31:01 and methotrexate-induced interstitial lung aisease in Japanese rheumatoid arthritis patients: A multi-drug hypersensitivity marker? Ann. Rheum. Dis. 72, 153-155 (2013).
91. Speerstra, F., Reekers, P., van de Putte, L. B., Vandenbroucke, J. P., Rasker, J. J. & de Rooij, D. J. HLA-DR antigens and proteinuria induced by aurothioglucose and D-penicillamine in patients with rheumatoid arthritis. J. Rheumatol. 10, 948-953 (1983).
92. Furukawa, H., Oka, S., Shimada, K., Sugii, S., Hashimoto, A. & Komiya, A. et al. HLA-DRB1∗08:02 is associated with bucillamine-induced proteinuria in Japanese rheumatoid arthritis patients. Biomark Insights 9, 23-28 (2014).
93. Tishler, M., Golbrut, B., Shoenfeld, Y. & Yaron, M. Anti-Ro(SSA) antibodies in patients with rheumatoid arthritis-a possible marker for gold induced side effects. J. Rheumatol. 21, 1040-1042 (1994).
94. Tishler, M., Paran, D. & Yaron, M. Allergic disorders in primary Sjogren's syndrome. Scand. J. Rheumatol. 27, 166-169 (1998).
95. Cruz-Tapias, P., Rojas-Villarraga, A., Maier-Moore, S. & Anaya, J. M. HLA and Sjogren's syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun. Rev. 11, 281-287 (2012).
96. Pachoula-Papasteriades, C., Boki, K., Varla-Leftherioti, M., Kappos-Rigatou, I., Fostiropoulos, G. & Economidou, J. HLA-A,-B, and -DR antigens in relation to gold and D-penicillamine toxicity in Greek patients with RA. Dis. Markers 4, 35-41 (1986).
97. Doyle, A. C. A Study in Scarlet. Beeton's Christmas Annual 28, 1-95 (1887).